Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Clinical metagenomic next-generation sequencing (mNGS), the comprehensive analysis of
microbial and host genetic material (DNA and RNA) in samples from patients, is rapidly …

Early detection has the potential to reduce cancer mortality, but an effective screening test
must demonstrate asymptomatic cancer detection years before conventional diagnosis in a …

Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

Methylation patterns of circulating cell-free DNA (cfDNA) contain rich information about
recent cell death events in the body. Here, we present an approach for unbiased …

The use of liquid biopsies for cancer detection and management is rapidly gaining
prominence. Current methods for the detection of circulating tumour DNA involve …

Thousands of pathogens are known to infect humans, but only a fraction are readily
identifiable using current diagnostic methods. Microbial cell-free DNA sequencing offers the …

Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology,
but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …